New Senior Executives Appointed at Sanofi:

Greg Irace, Senior Vice President, Global Services

PARIS, July 22, 2011 /PRNewswire/ -- Sanofi (EURONEXT : SAN ; NYSE : SNY) is pleased to announce today the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services. In his new role, Greg will lead the Global Information Systems function, be responsible for shared support functions across all Sanofi businesses in North America and play a key role in the development of a global strategy for shared services. Greg will report to Jerome Contamine, Executive Vice President, Chief Financial Officer, and will continue to be a member of the Global Management Committee. He will be based in Bridgewater, New Jersey.

(Logo:  http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

Jerome Contamine, Executive Vice President, Chief Financial Officer, Sanofi, commented: "The integration of Genzyme and Merial gives Sanofi the opportunity to create a platform of shared support functions to serve Sanofi's five North American businesses and its more than 20,000 employees.  I am confident that Greg's dedication and the leadership he has shown in his previous roles will result in his leading this new organization to great success."

Anne C. Whitaker will join Sanofi as President, North America, Pharmaceuticals, effective September 1, 2011.  She will report to Hanspeter Spek, President, Global Operations and will join the Global Management Committee.  She will be based in Bridgewater, New Jersey.

Hanspeter Spek, President, Global Operations, Sanofi, declared: "The knowledge and experience Anne has gained through her previous roles in Sales, Marketing and Leadership Development in the Pharmaceutical industry, particularly in the United States, make her ideally suited to drive the renewed growth of our pharmaceutical operations in North America."

Anne joins Sanofi from GSK, where she was Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology, since 2009.  Anne holds a Bachelors degree in Chemistry and Business Administration from the University of North Alabama.  She began her career at Delta Communications and joined the Upjohn Company in 1991 as a metabolic disease specialist.  She joined GSK in 1992 as a sales representative and held various positions in Sales and Training.  In 2001, she became Vice President of Critical and Supportive Care, a Business Division based in Pennsylvania, before being appointed Senior Vice President of Leadership and Organization Development, based in London, England, from 2008 to 2009.

Greg Irace holds a B.S. in accounting from Albany State University. He began his career at Price Waterhouse in 1980 and received his CPA in 1982. He spent 11 years at Price Waterhouse becoming a Senior Audit Manager in 1988, and a Senior Manager in the Corporate Finance Department in 1989. In 1991, he joined Sterling Winthrop Inc. and became in 1993 Director of Financial Planning and Analysis, and then Chief Financial Officer of Sanofi's Pharmaceutical Operations in the United States in 1994. He has held his current responsibilities for the US operations since 2007.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:




Media Relations

Investor Relations

Jean-Marc Podvin (Paris)

Sebastien Martel

Tel.: + (33) 1 53 77 46 46

Tel.: + (33) 1 53 77 45 45

[email protected]

[email protected]



Jack Cox (North America)


Office: 908-981-5280


[email protected]




SOURCE Sanofi

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.